In August, the federal government announced the lower negotiated prices for 10 medications, which include therapies for Type 2 diabetes, blood clots and heart failure. The new prices — which are estimated to reduce healthcare costs by $7.5 billion — will go into effect Jan. 1, 2026.
For the next phase, CMS will select up to 15 medications to undergo negotiations for lower list prices to take effect Jan. 1, 2027. Multiple cancer therapies are predicted to be chosen, and CMS will announce the selected drugs by February.
In contrast to the first round of negotiations, CMS will hold up to 15 patient-focused roundtables and one town hall that weighs the clinical considerations, according to a 313-page final guidance published Oct. 2.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.